In addition, silencing ET1 or using ETR inhibitors has been shown to lower HIF-1α and VEGF levels in endothelial [42] cells and reduce angiogenesis in chondrosarcoma [43], ovarian cancer [44] and melanoma cells [33,45]. This evidence concerns the gene EDN1 and ovarian carcinoma.